Fuad El-Hibri Net Worth

The estimated Net Worth of Fuad El Hibri is at least $98.6 Million dollars as of 9 November 2020. Mr. Hibri owns over 39,391 units of Emergent Biosolutions Inc stock worth over $8,655,379 and over the last 18 years he sold EBS stock worth over $86,890,614. In addition, he makes $3,010,060 as Executive Chairman of the Board at Emergent Biosolutions Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Hibri EBS stock SEC Form 4 insiders trading

Fuad has made over 79 trades of the Emergent Biosolutions Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 39,391 units of EBS stock worth $1,041,892 on 9 November 2020.

The largest trade he's ever made was selling 119,341 units of Emergent Biosolutions Inc stock on 9 December 2014 worth over $3,102,866. On average, Fuad trades about 17,069 units every 23 days since 2006. As of 9 November 2020 he still owns at least 1,143,379 units of Emergent Biosolutions Inc stock.

You can see the complete history of Mr. Hibri stock trades at the bottom of the page.

Fuad El-Hibri biography

Fuad El-Hibri is an Executive Chairman of the Board of the Company. Since August 2016, has served as the chairman of the board of directors of Aptevo Therapeutics Inc. From June 2004 to March 2012, Mr. El-Hibri served as chief executive officer and as chairman of our Board of Directors. Mr. El-Hibri previously served as president from March 2006 to April 2007. Mr. El-Hibri served as chief executive officer and chairman of the board of directors of BioPort Corporation from May 1998 until June 2004, when, as a result of our corporate reorganization, BioPort became a wholly owned subsidiary of Emergent BioSolutions and was subsequently renamed as Emergent BioDefense Operations Lansing Inc. Mr. El-Hibri is chairman of East West Resources Corporation, a venture capital and business consulting firm, a position he has held since June 1990. He served as president of East West Resources from September 1990 to January 2004. Mr. El-Hibri is a member of the advisory board of the Yale Healthcare Conference, a member of the board of directors of the International Biomedical Research Alliance, an academic joint venture among the National Institutes of Health, or NIH, Oxford University and Cambridge University. He also serves as chairman of the El-Hibri Foundation. Mr. El-Hibri has also served as a member of the board of trustees of American University from 2004 to 2010 and a member of the board of directors of the U.S. Chamber of Commerce from 2011 to 2017. Mr. El-Hibri received a master's degree in public and private management from Yale University and a B.A. in economics from Stanford University.

What is the salary of Fuad Hibri?

As the Executive Chairman of the Board of Emergent Biosolutions Inc, the total compensation of Fuad Hibri at Emergent Biosolutions Inc is $3,010,060. There are 1 executives at Emergent Biosolutions Inc getting paid more, with Robert Kramer having the highest compensation of $3,693,820.

How old is Fuad Hibri?

Fuad Hibri is 62, he's been the Executive Chairman of the Board of Emergent Biosolutions Inc since 2012. There are 9 older and 11 younger executives at Emergent Biosolutions Inc. The oldest executive at Emergent Biosolutions Inc is Louis Sullivan, 86, who is the Independent Director.

What's Fuad Hibri's mailing address?

Fuad's mailing address filed with the SEC is C/O APTEVO THERAPEUTICS INC., 2401 4TH AVENUE, SUITE 1050, SEATTLE, WA, 98121.

Insiders trading at Emergent Biosolutions Inc

Over the last 18 years, insiders at Emergent Biosolutions Inc have traded over $131,382,266 worth of Emergent Biosolutions Inc stock and bought 4,647 units worth $138,981 . The most active insiders traders include Seamus Mulligan, Fuad El Hibri, and Shahzad Malik. On average, Emergent Biosolutions Inc executives and independent directors trade stock every 21 days with the average trade being worth of $147,206. The most recent stock trade was executed by Kathryn C Zoon on 4 June 2024, trading 10,000 units of EBS stock currently worth $61,100.

What does Emergent Biosolutions Inc do?

emergent biosolutions is a global life sciences company dedicated to one simple mission—to protect and enhance life. we develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. through our work, we envision protecting and enhancing 50 million lives with our products by 2025. additional information about the company may be found at www.emergentbiosolutions.com. follow us @emergentbiosolu and @life_at_emergent

Complete history of Mr. Hibri stock trades at Aptevo Therapeutics Inc and Emergent Biosolutions Inc

Emergent Biosolutions Inc executives and stock owners

Emergent Biosolutions Inc executives and other stock owners filed with the SEC include:

• Robert Kramer,
  President, Chief Executive Officer, Director
• Fuad El-Hibri,
  Executive Chairman of the Board
• Robert G. Kramer,
  CEO, Pres & Exec. Director
• Richard Lindahl,
  Chief Financial Officer, Executive Vice President, Treasurer
• Atul Saran,
  Executive Vice President, Corporate Development, General Counsel and Corporate Secretary
• Adam Havey,
  Executive Vice President - Business Operations
• Fuad El-Hibri,
  Founder & Exec. Chairman
• Richard S. Lindahl,
  Exec. VP, CFO & Treasurer
• Adam R. Havey,
  Exec. VP & COO
• Atul Saran,
  Exec. VP of Corp. Devel. & Ext. Affairs and Gen. Counsel
• Seamus Mulligan,
  Director
• Ronald Richard,
  Lead Independent Director
• Zsolt Harsanyi,
  Independent Director
• Louis Sullivan,
  Independent Director
• Jerome Hauer,
  Independent Director
• George Joulwan,
  Independent Director
• Kathryn Zoon,
  Independent Director
• Sue Bailey,
  Independent Director
• Marvin White,
  Director
• Robert Burrows,
  Vice President, Investor Relations
• Sean Kirk,
  Executive Vice President, Manufacturing and Technical Operations
• Katherine Strei,
  Executive Vice President, Human Resources and Communications, Chief Human Resources Officer
• Katherine Strei,
  Exec. VP of HR & Chief HR Officer
• Nina DeLorenzo,
  Sr. VP of Global Communications & Public Affairs
• Lynn Kieffer,
  VP of Corp. Communications
• Howard Anderson,
  Sr. VP & Chief Information Officer
• Karen L. Smith,
  EVP, Chief Medical Officer
• John Niederhuber,
  Director
• Daniel Abdun Nabi,
  SVP Corp Aff, GC & Secretary
• L.L.C. Bio Pharm,,
  10% owner
• Stephen Lockhart,
  SVP Product Development
• L.L.C. Intervac,,
  10% owner
• Steven Chatfield,
  President, EPD UK & CSO
• R Don Elsey,
  VP Finance, CFO & Treasurer
• Barry Labinger,
  EVP, Biosciences Div.
• Denise Esposito,
  SVP Legal Affairs & GC
• L.L.C. Biologika,,
  
• Biologic Products, Inc. Mic...,
  
• Kyle Keese,
  SVP Mktg & Comm.
• Joe M Allbaugh,
  Director
• Mauro Gibellini,
  SVP Corporate Dev.
• Investments Ltd Microscience,
  10% owner
• Shahzad Malik,
  Director
• Edward Arcuri,
  EVP & COO
• Thomas Zink,
  SVP & CMO
• Robert Calvin Myers,
  
• Joseph C Papa,
  President and CEO
• Jennifer Lynne Fox,
  EVP, Ext Aff, GC, Corp Sec
• Keith Katkin,
  Director
• Coleen Glessner,
  EVP, Quality & Ethics, and CPL
• Sujata Tyagi Dayal,
  Director
• Paul Anthony Williams,
  SVP, Products Business
• William Hartzel,
  SVP, Bioservices
• Neal Franklin Fowler,
  Director
• Donald W De Golyer,
  Director